An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

Gertjan J.L. Kaspers; Denise Niewerth; Bram A.J. Wilhelm; Peggy Scholte-van Houtem; Marta Lopez-Yurda; Johannes Berkhof; Jacqueline Cloos; Valerie de Haas; Ron A. Mathôt; Andishe Attarbaschi; André Baruchel; Eveline S. de Bont; Franca Fagioli; Claudia Rössig; Thomas Klingebiel; Barbara De Moerloose; Brigitte Nelken; Giuseppe Palumbo; Dirk Reinhardt; Pierre Simon Rohrlich; Pauline Simon; Arend von Stackelberg; Christian Michel Zwaan

doi:10.1111/bjh.15233

An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

Gertjan J.L. Kaspers, Denise Niewerth, Bram A.J. Wilhelm, Peggy Scholte-van Houtem, Marta Lopez-Yurda, Johannes Berkhof, Jacqueline Cloos, Valerie de Haas, Ron A. Mathôt, Andishe Attarbaschi, André Baruchel, Eveline S. de Bont, Franca Fagioli, Claudia Rössig, Thomas Klingebiel, Barbara De Moerloose, Brigitte Nelken, Giuseppe Palumbo, Dirk Reinhardt, Pierre Simon RohrlichPauline Simon, Arend von Stackelberg, Christian Michel Zwaan

Research related

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

11 Citaten (Scopus)

Samenvatting

This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m ² /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.

Originele taal-2	Engels
Pagina's (van-tot)	523-527
Aantal pagina's	5
Tijdschrift	British Journal of Haematology
Volume	181
Nummer van het tijdschrift	4
DOI's	https://doi.org/10.1111/bjh.15233
Status	Gepubliceerd - mei 2018

Toegang tot document

10.1111/bjh.15233

Citeer dit

Kaspers, G. J. L., Niewerth, D., Wilhelm, B. A. J., Scholte-van Houtem, P., Lopez-Yurda, M., Berkhof, J., Cloos, J., de Haas, V., Mathôt, R. A., Attarbaschi, A., Baruchel, A., de Bont, E. S., Fagioli, F., Rössig, C., Klingebiel, T., De Moerloose, B., Nelken, B., Palumbo, G., Reinhardt, D., ... Zwaan, C. M. (2018). An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 181(4), 523-527. https://doi.org/10.1111/bjh.15233

@article{792b0082b19c4bd39ee608627e715a6a,

title = "An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia",

abstract = " This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m 2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.",

keywords = "acute leukaemia, bortezomib, childhood leukaemia, pharmacokinetics, proteasome inhibitor",

author = "Kaspers, {Gertjan J.L.} and Denise Niewerth and Wilhelm, {Bram A.J.} and {Scholte-van Houtem}, Peggy and Marta Lopez-Yurda and Johannes Berkhof and Jacqueline Cloos and {de Haas}, Valerie and Math{\^o}t, {Ron A.} and Andishe Attarbaschi and Andr{\'e} Baruchel and {de Bont}, {Eveline S.} and Franca Fagioli and Claudia R{\"o}ssig and Thomas Klingebiel and {De Moerloose}, Barbara and Brigitte Nelken and Giuseppe Palumbo and Dirk Reinhardt and Rohrlich, {Pierre Simon} and Pauline Simon and {von Stackelberg}, Arend and Zwaan, {Christian Michel}",

note = "Publisher Copyright: {\textcopyright} 2018 John Wiley & Sons Ltd",

year = "2018",

month = may,

doi = "10.1111/bjh.15233",

language = "English",

volume = "181",

pages = "523--527",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

Kaspers, GJL, Niewerth, D, Wilhelm, BAJ, Scholte-van Houtem, P, Lopez-Yurda, M, Berkhof, J, Cloos, J, de Haas, V, Mathôt, RA, Attarbaschi, A, Baruchel, A, de Bont, ES, Fagioli, F, Rössig, C, Klingebiel, T, De Moerloose, B, Nelken, B, Palumbo, G, Reinhardt, D, Rohrlich, PS, Simon, P, von Stackelberg, A & Zwaan, CM 2018, 'An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia', British Journal of Haematology, vol. 181, nr. 4, blz. 523-527. https://doi.org/10.1111/bjh.15233

TY - JOUR

T1 - An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

AU - Kaspers, Gertjan J.L.

AU - Niewerth, Denise

AU - Wilhelm, Bram A.J.

AU - Scholte-van Houtem, Peggy

AU - Lopez-Yurda, Marta

AU - Berkhof, Johannes

AU - Cloos, Jacqueline

AU - de Haas, Valerie

AU - Mathôt, Ron A.

AU - Attarbaschi, Andishe

AU - Baruchel, André

AU - de Bont, Eveline S.

AU - Fagioli, Franca

AU - Rössig, Claudia

AU - Klingebiel, Thomas

AU - De Moerloose, Barbara

AU - Nelken, Brigitte

AU - Palumbo, Giuseppe

AU - Reinhardt, Dirk

AU - Rohrlich, Pierre Simon

AU - Simon, Pauline

AU - von Stackelberg, Arend

AU - Zwaan, Christian Michel

PY - 2018/5

Y1 - 2018/5

N2 - This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m 2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.

AB - This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m 2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.

KW - acute leukaemia

KW - bortezomib

KW - childhood leukaemia

KW - pharmacokinetics

KW - proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85047878463&partnerID=8YFLogxK

U2 - 10.1111/bjh.15233

DO - 10.1111/bjh.15233

M3 - Article

C2 - 29676440

AN - SCOPUS:85047878463

SN - 0007-1048

VL - 181

SP - 523

EP - 527

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit